Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00430534
Status:
COMPLETED
Last Update Posted:
2007-02-02
First Post:
2007-02-01
Brief Title:
Evaluation of Safety Immune-Response and Efficacy of GSK Biologicals EBV Epstein Barr Virus Vaccine 268664
Sponsor:
Henogen
Organization:
Henogen
Study Overview
Official Title:
To Evaluate the Safety Immunogenicity and Efficacy of GSK Biologicals EBV Vaccine 268664 in Healthy Seronegative AdolescentsAdults When Injected Intramuscularly According to a 0-1-5 Month Schedule in Belgium
Status:
COMPLETED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety immune-response and efficacy of GSK Biologicals EBV vaccine in a population at risk of developing infectious mononucleosis Each subject will receive three doses of vaccine or placebo during the study period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None